News

Zydus Cadila announced that the company has received the Emergency Use Authorization (EUA) from the Drug Controller General of India (DCGI) for ZyCoV-D, the world’s first Plasmid DNA Vaccine for COVID-19.

A new study published in Oncotarget suggests that terpyridine platinum-derived G4 ligands could be used as a cancer treatment approach, by inducing telomere dysfunction and chromosome instability.

Tiny brains-in-a-dish that mimic the major pathological features of Parkinson’s disease have been made for the first time. The research offers a new way to study how the degenerative brain disease progresses and explore possible new treatments.

Researchers have combined the health records of over six million patients and found no serious health effects that could be linked to the 2 mRNA COVID-19 vaccines.

Researchers have generated the first “atlas” of human melanocytes. In analyzing the atlas data, it was discovered that there are different types of melanocytes and researchers predict these discoveries will lead to more targeted treatments for melanoma.

Degeneration of the discs that cushion and support vertebrae, a common occurrence of aging, is a major contributor to low back pain. Although a widespread condition, few treatments are available. Researchers have now shown that treating mice with a drug cocktail that removes aging cells reduces disc degeneration.

Researchers from the University of Oxford and the Ludwig Institute for Cancer Research are harnessing the viral vector technology used to create the Oxford–AstraZeneca vaccine against SARS-CoV-2 to develop a vaccine to treat cancer.

Vaccinations against human papillomavirus (HPV) are expected to yield significant reductions in the rates of throat and mouth cancers in the U.S., but will not do so until after 2045, according to a new modeling study.

Researchers have discovered a novel mechanism showing how a certain gene mutation allows tumors to evade detection by the immune system in colorectal cancer patients.

Researchers attempting to develop rheumatoid arthritis therapies with minimal side effects have genetically engineered cells that deliver a biologic drug in response to inflammation.